Applications of Carbon Dots for the Treatment of Alzheimer's Disease
DOI: https://doi.org/10.2147/IJN.S388030
IF: 7.033
2022-12-23
International Journal of Nanomedicine
Abstract:Feng Guo, 1, &ast Qingman Li, 1, &ast Xiaolin Zhang, 2, &ast Yiheng Liu, 3 Jie Jiang, 4 Shuanghuai Cheng, 1 Si Yu, 1 Xingfang Zhang, 1, 5 Fangfang Liu, 6 Yiying Li, 1 Gregory Rose, 7 Haiying Zhang 1 1 Public Research Laboratory of Hainan Medical University, Haikou, 571199, People's Republic of China; 2 Key Laboratory of Child Cognition & Behavior Development of Hainan Province, Qiongtai Normal University, Haikou, 571127, People's Republic of China; 3 Haikou Hospital Affiliated to Central South University Xiangya School of Medicine, Haikou, 570208, People's Republic of China; 4 Scientific Experiment Center of Hainan Medical University, Haikou, 571199, People's Republic of China; 5 The First Affiliated Hospital of Hainan Medical College, Haikou, 570102, People's Republic of China; 6 Laboratory Department, Nanping First Hospital Affiliated to Fujian Medical University, Fujian, 353006, People's Republic of China; 7 Departments of Anatomy and Physiology, Southern Illinois University School of Medicine, Carbondale, IL, 62901, USA &astThese authors contributed equally to this work Correspondence: Gregory Rose, Departments of Anatomy and Physiology, Southern Illinois University School of Medicine, Carbondale, IL, 62901, USA, Tel +1 618-303-6503, Email Haiying Zhang, Public Research Laboratory of Hainan Medical University, Haikou, 571199, People's Republic of China, Tel +86 13907533247, Email There are currently approximately 50 million victims of Alzheimer's disease (AD) worldwide. The exact cause of the disease is unknown at this time, but amyloid plaques and neurofibrillary tangles in the brain are hallmarks of the disease. Current drug treatments for AD may slow the progression of the disease and improve the quality of life of patients, but they are often only minimally effective and are not cures. A major obstacle to developing and delivering more effective drug therapies is the presence of the blood-brain barrier (BBB), which prevents many compounds with therapeutic potential from reaching the central nervous system. Nanotechnology may provide a solution to this problem. Among the medical nanomaterials currently being studied, carbon dots (CDs) have attracted widespread attention because of their ability to cross the BBB, non-toxicity, and potential for drug/gene delivery. Graphical Keywords: Alzheimer's disease, blood-brain barrier, nanoparticles, carbon dots, gene delivery Graphical Alzheimer's dementia is one of the greatest global challenges for health and social care in the 21st century. Approximately 50 million people worldwide currently suffer from Alzheimer's disease, and the number is expected to triple by 2050. While there are many different illnesses that can cause dementia, Alzheimer's disease (AD) is the most common. 1,2 AD results in a progressive deterioration of brain function, initially characterized by cognitive deficits, with loss of recent memory and language ability, impairment of orientation, problem solving, and abstract thinking. 3 The pathophysiology of AD is very complex, but has the primary histopathological features in the brain of extracellular plaques comprised of amyloid β (Aβ) and intracellular neurofibrillary tangles (NFTs) comprised of hyperphosphorylated tau protein. 4–6 Although great progress has been made in exploring the etiology of AD, the exact pathogenesis of the disease is still unclear. 7 Since patients with more advanced disease require full-time care, AD imposes a heavy burden on both families and society. 8 Currently there are two classes of drugs that are most used for the treatment of AD: acetylcholinesterase inhibitors, which act to boost brain levels of acetylcholine, a neurotransmitter known to play an important role in cognition, 9–13 and an antagonist to the glutamatergic N-methyl d-aspartate (NMDA) receptor, which seem to act by preventing overactivation of excitatory neurotransmission. 14 Very recently, a third approach to the treatment of AD was approved for use in the United States. The drug, aducanumab, is a monoclonal antibody that acts to remove amyloid from the brain. However, currently available clinical data indicate that the drug is, at best, only marginally effective, fails to protect patients from cognitive and functional decline, and carries significant risks including brain swelling. 15 Thus, currently available treatments for AD have limited efficacy, marginally slowing symptom progression in AD patients, and cannot prevent the progress of brain damage, or cu -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology